GRAIL Faces Class Action Over Failed NHS-Galleri Cancer Trial

The litigation targets the period between May 13, 2025, and February 19, 2026, focusing on claims that GRAIL executives repeatedly touted the trial’s design while withholding internal data. According to the complaint, the company failed to disclose that the three-year follow-up period was insufficient to reach its primary endpoint—a reduction in late-stage cancer diagnoses. Instead, the firm allegedly promoted favorable top-line results to maintain investor confidence in the study’s path to global expansion.

On February 19, 2026, the company conceded that the trial failed to meet its primary goal and admitted that a longer follow-up period likely should have been utilized. Reed Kathrein, the Hagens Berman partner leading the investigation, stated that the firm is now scrutinizing exactly when management realized the trial’s duration was fundamentally misaligned with its public claims. Investors who suffered losses during the class period have until August 4, 2026, to move for appointment as lead plaintiff. Hagens Berman is also soliciting information from potential whistleblowers who may have knowledge of the internal decision-making process regarding the trial design.